ArticleDiscover oncology2025
Efficacy and safety analysis of DEB-TACE for hepatocellular carcinoma with portal vein tumor thrombosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- DEB-TACE-HAIC combined with donafenib and camrelizumab in the treatment of unresectable hepatocellular carcinoma: a multicenter retrospective study.Frontiers in immunology · 2026Article
- Efficacy and Safety of Thermosensitive Hydrogel Combined with Pirarubicin via TACE for Hepatocellular Carcinoma: A Pilot Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) with different types of portal vein tumor thrombosis (PVTT). PATIENTS AND
methodsFifty patients with HCC complicated with PVTT from August 2016 to January 2021 were selected as subjects, all of whom were treated with DEB-TACE. According to PVTT classification, the patients were divided into type I (n = 10), type II (n = 16) and type III (n = 24). The therapeutic efficacy was evaluated after 1 month of treatment, the changes in liver function indexes and tumor markers were statistically analyzed, and patients' prognosis was evaluated.
resultsThe three groups manifested no difference in disease response rate and disease control rate (P > 0.05). Before DEB-TACE, albumin (ALB), total bilirubin (TBIL), alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) in type III and type II groups were higher than those in type I group, and ALB and ALT in type III group were higher than those in type II group (P < 0.05). After DEB-TACE, ALB, TBIL, ALT, and AST in type III and type II groups were lowered, as well as TBIL, ALT, and AST in type I group (P < 0.05). Before DEB-TACE, α-fetoprotein (AFP) and PIVKA-II in type I group were the lowest, followed by type II and type III groups (P < 0.05). AFP and PIVKA-II in patients with different PVTT types after DEB-TACE were lower than those before DEB-TACE (P < 0.05). The survival rates of type I, type II, and type III groups were 70.00% (7/10), 31.25% (5/16), and 28.00% (7/24), respectively. The survival rates of type II and type III PVTT patients were lower than those of type I patients (P < 0.05). No significant difference was shown in the survival rates of type II and type III PVTT patients (P > 0.05). The median survival time of type II group was 17 months, which was higher than that of type III group (12.5 months) (the survival rate of type I group was higher than 50%, with no median survival time).
conclusionDEB-TACE has high clinical efficacy on HCC complicated with PVTT, which can improve liver function and suppress tumor markers. The survival rate of type II and type III PVTT patients after DEB-TACE is lower than that of type I PVTT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.